Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.
Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...
Pfizer Lyme vaccine candidate shows over 70% efficacy in phase 3 trial and moves forward with FDA regulatory submission.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results